Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Nektar Therapeutics
Nektar Therapeutics
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Ingredients
Therapeutic: rezpegaldesleukin for dermatitis
Atopic dermatitis remains an unmet medical need, with better and more effective treatments still required for the one in 10 people who are affected
Regulatory
Anticancer agent – etirinotecan pegol
Nektar Therapeutics has developed a pegylated tetrameric derivative of irinotecan that is designed to preferentially penetrate tumour vasculature ahead of normal vasculature
Pharmaceutical
Ivan Gergel becomes SVP, Drug Development & Chief Medical Officer at Nektar Therapeutics
Joins the company from Endo Pharmaceuticals
Regulatory
Opioid-induced constipation – naloxegol
About half of all patients taking opioids commonly experience constipation
Subscribe now